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This paper evaluates patient-specific quality assurance (PSQA) in the treatment of small and 
multiple tumors by the CyberKnife system with fixed collimators, using an ion chamber and EBT3 
films. We selected 49 patients with single or multiple brain tumors, and the treatment plans include 
one to four targets with total volumes ranging from 0.12 cc to 3.74 cc. All PSQA deliveries were 
performed with a stereotactic dose verification phantom. The A16 microchamber (Standard 
Imaging, WI, USA) and Gafchromic EBT3 film (Ashland ISP Advanced Materials, NJ, USA) were 
inserted into the phantom to measure the point dose of the target and the dose distribution, 
respectively. The film was scanned 1 hr after irradiation by a film digitizer scanner and analyzed 
using RIT software (Radiological Imaging Technology, CO, USA). The acceptance criteria was <5% 
for the point dose measurement and >90% gamma passing rate using 3%/3 mm and relative dose 
difference, respectively. The point dose errors between the calculated and measured dose by the 
ion chamber were in the range of −17.5% to 8.03%. The mean point dose differences for 5 mm, 7.5 
mm, and 10 mm fixed cone size was −11.1%, −4.1%, and −1.5%, respectively. The mean gamma 
passing rates for all cases was 96.1%. Although the maximum dose distribution of multiple targets 
was not shown in the film, gamma distribution showed that dose verification for multiple tumors 
can be performed. The use of the microchamber and EBT3 film made it possible to verify the 
dosimetric and mechanical accuracy of small and multiple targets. In particular, the correction 
factors should be applied to small fixed collimators less than 10 mm.
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Introduction
CyberKnife M6 (Accuray Inc, Sunnyvale, CA) is frameless 
and Image-guided robotic radiosurgery system (Fig. 1). It 
has almost 1000 monitor unit (MU)/min high dose-rate 
and 6 MV flattening filter free treatment beam with non-
coplanar beam geometry. It is suitable to treat for stereo-
tactic radiosurgery (SRS) or stereotactic radiotherapy (SRT) 
for small and multiple brain tumors. It provides three types 
of collimator: fixed collimator, IRISTM variable aperture 
collimator, and InCiseTM2 multileaf collimator (MLC).1) 
The IRISTM collimator that allows the field size to be varied 
during treatment is applicable to a target that may not be 
spherical in shape requiring multiple collimator sizes. MLC 
can be considered for multiple brain tumors because fields 
are shaped to match the tumor closely and the delivery 
time is reduced. However, due to a limit of leaf width (3.85 
mm), it is hard to cover the small size tumor and small 
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changes in small field size can significantly affect the dose 
delivered.2,3) For target coverage, the fixed collimator can 
be a useful modality but it is challenging when patient-
specific quality assurance (PSQA) is performed because of 
lateral electronic disequilibrium, steep dose gradients, and 
complex dose distribution generated by multi-directional 
beams.4,5) To overcome these issues, we focus on PSQA for 
multiple brain tumors with small circular photon beams of 
diameter 5 to 25 mm in CyberKnife with a fixed collimator. 
In this study, PSQAs were performed with the stereotactic 
dose verification phantom (SDVP; Standard Imaging, WI, 
USA), which includes the Exradin A16 microchamber6) 
(Standard Imaging, WI, USA) and Gafchromic EBT3 film 
(Ashland ISP Advanced Materials, NJ, USA).
Materials and Methods
1. Patient selection and delivery for the small field
49 patient plans with single or multiple brain tumors 
were selected for this study. The plans had 1 to maximum 
4 targets with total volumes ranging from 0.12 cc to 3.74 cc 
(diameter 6.1 mm–19.3 mm), approximately. Table 1 shows 
the characteristics of patient plans. Each CyberKnife plan 
was created by using a single fixed collimator only. 
The accuracy of planning and delivery was evaluated by 
delivering treatment plans to the SDVP. As Fig. 2, the A16 
microchamber (0.007 cm3)6) and Gafchromic EBT3 film 
were inserted into the phantom to measure the central 
dose of the target and relative dose distribution, respective-
ly. EBT3 film was cut by using Laser cutting system.7) The 4 
gold fiducial markers within the SDVP phantom were used 
for matching between live digitally reconstructed radio-
graphs (DRRs) and DRRs created by planning CT images. 
The active volume of the ionization chamber was located 
Table 1. The properties of CyberKnife® plans for brain tumors.
CyberKnife® Plans Number of patients
Fixed cone size
   5.0 mm 9
   7.5 mm 12
   10.0 mm 15
   12.5 mm 9
   20.0 mm 3
   25.0 mm 1
   Total 49
Number of tumors
   1 34
   2 9
   3 5
   4 1
   Total 49
Tumor size
   diameter ≤ 7.5 mm 7
   7.5 mm < diameter ≤ 10.0 mm 17
   10.0 mm < diameter ≤ 12.5 mm 7
   12.5 mm < diameter ≤ 15.0 mm 2
   15.0 mm < diameter ≤ 17.5 mm 5
   17.5 mm < diameter ≤ 20.0 mm 5
   20.0 mm < diameter 7
   Total 49
a b
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Fig. 1. Overview of CyberKnife M6 
system: (a) Schematics of CyberKnife 
mounted with the fixed collimator 
and x-ray live imagers installed on 
the ceiling and (b) fixed collimators: 
5.0, 7.5, 10.0, 12.5 and 15.0 mm for 
brain tumors. 60 mm for dosimetric 
quality assurance.
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in a gentle dose gradient region within target volumes. 
2. Radiochromic EBT3 films and digitization
Gafchromic self-developing EBT3 films are widely used 
for the dosimetric verification of treatment planning sys-
tems and more generally for the QA of linear accelerators. 
EBT3 films have a high spatial resolution (~25 um) recom-
mended for the quality control of small fields and high-
gradient dose distributions. 
To correctly evaluate the gamma analysis, we made the 
film calibration curve representing the relationship be-
tween dose and intensity in the range of 0.1 Gy to 18 Gy. 
The absolute dose was measured using Farmer chamber at 
5 cm depth from the phantom surface (Fig. 3a). EBT3 Films 
were then irradiated within a solid water slab phantom at 5 
cm depth at source-to-surface distance (SSD) of 100 cm by 
using a 6 MV photon (Fig. 3b). The EBT3 film was scanned 
and digitized 1 hr after irradiation by the Vidar scanner and 
analyzed using RIT software (Radiological Imaging Tech-
nology, CO, USA). The digitized pixel value was the range 
of 0–216−1. To consider the measurement uncertainty, the 
calibration curve was fitted by an exponential function (Fig. 
3c).
3. PSQA plan and acceptance criteria
We used MultiPlan 5.1.2 (Accuray Inc., CA, USA). QA 
template plan was created using fiducial tracking method, 
which is compatible with all of the tracking method for 
a b
Stereotatic Dose Verification Phantom (SDVP)
Exradin A16 ion chamber
(2.4mm dia., 0.007 cc vol.)
Laser cutting
Fig. 2. PSQA measurement setup: 
(a) SDVP with Exradin A16 micro-
chamber and (b) a customized EBT3 
film.
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Fig. 3. Film calibration using RW3 water-equivalent phantom: (a) Absolute dose measurement setup with Farmer chamber, (b) EBT3 film 
placed at the same position, and (c) the calibration curve for EBT3 film. The measured pixel values were fitted by an exponential function.
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patient plans. The sensitive area of the ionization chamber 
and the film area were selected as the volume of interests 
(VOIs) on the QA template plan. When creating PSQA plan, 
a target in patient plan was corresponded to the VOI rep-
resenting the sensitive area of the ionization chamber. MU 
was then rescaled to reduce the beam delivery time. The 
calculated coronal view representing 2D dose distribution 
was exported from MultiPlan.
The gamma analysis was conducted for all CyberKnife 
plans. Acceptance criteria for dosimetric accuracy were 
≤±5% for the point dose measurement and ≥90% gamma 
passing rate using 3%/3 mm, applied 10% threshold dose, 
respectively.8) The point dose error was calculated as 
[(Dmeas–Dcal)/Dcal]×100%. Dmeas means measured dose by 
ion chamber and Dcal is a calculated dose by treatment 
planning system. Under 10 mm fixed cones, the correc-
tion factor was applied to measured dose. The point dose 
error was calculated as [(Dmeas×CF−Dcal)/Dcal]×100%. CF is 
correction factor for ion chamber considering small field 
effect.9-11)
Results
Fig. 4 shows the point dose difference between the calcu-
lated and measured doses when using the fixed collimator 
with cone size of 5.0 mm, 7.5 mm, 10.0 mm, 12.5 mm, 20 
mm, and 25 mm. In particular, the point dose error was un-
derestimated as −11.3%, −4.1% and −1.5% for fixed cones of 
5 mm, 7.5 mm and 10.0 mm, respectively. These underesti-
mations depended on the size of the fixed collimator due to 
volume effect of a detector and charged particle disequilib-
rium. Based on the correction factor calculated by Monte 
Carlo simulation of A16 microchamber in CyberKnife M6,9) 
we corrected the measured dose by applying 1.099, 1.025, 
and 1.013 for fixed cones of 5.0 mm, 7.5 mm, and 10.0 mm, 
respectively. When these correction factors were applied 
to fixed cones of 5 mm, 7.5 mm, and 10.0 mm, the range of 
the point dose error was significantly decreased as −4.8%, 
−2.2% and −0.7%, respectively. Thereby, the point dose er-
ror were within ±5% of tolerance and failed plans were only 
a few percentages outside tolerance. 
The dose distribution of multiple tumors had patterns 
depending on the number and position of targets (Fig. 5a). 
Dose distribution for multiple tumors can be confirmed 
in the film plane (Fig. 5b). Although the maximum dose 
of the target did not appear on the film, the gamma distri-
bution in the film made it possible to verify the dose and 
beam direction for multiple tumors. In Fig. 6, we analyzed 
the gamma passing rate for the size of the fixed collimator 
and the number of tumors. The mean gamma passing rates 
for all cases was 96.1%. Based on results, gamma passing 
rate was not dependent on the size of fixed collimator and 
number of tumors.
Discussion
PSQA was used to confirm that the Cyberknife plan was 
delivered correctly. For brain tumors, fixed collimators 
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Fig. 4. Point dose error applied (a) without correction factor and (b) with correction factor by Monte Carlo simulation [10]. Boxes 
represent the interquartile range and horizontal lines inside each box represent the median.
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were used to achieve high target coverage. In this study, we 
observed that the point dose measured through the cham-
ber was underestimated by the collimator size. Therefore, 
it is necessary to apply a correction factor to the volume of 
ion chamber and fixed collimator in case of small size tu-
mors. Previous studies have reported that a correction fac-
tor using a single fixed collimator can be applied to a point 
dose measurement, but composite collimators cannot be 
applied.11) Our CyberKnife plan used only one fixed colli-
mator. It allowed us to implement a correction factor to ad-
just the point dose measured with the A16 ion chamber. As 
a result of applying the correction factor, we confirmed that 
the point dose error of CyberKnife plan was within ±5%. 
As a result of gamma evaluation using EBT3 film, we found 
that most plans have a gamma passing rate of over 90%. We 
also confirmed that the fixed collimator size or the number 
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Fig. 6. Gamma passing rate related to (a) the size of the fixed collimator and (b) the number of tumors. Boxes represent the interquartile 
range and horizontal lines inside each box represent the median.
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Fig. 5. Dose (a–d) distributions for CyberKnife plans with various cone sizes and the number of targets and its gamma (e–h) pass/failure 
(gamma index >1 is red color. (a) and (e) results of 5 mm fixed cone and single target. (b) and (f) 7.0 mm fixed cone and 2 targets. (c) and 
(g) 10.0 mm and 3 targets, (d) and (h) 10.0 mm fixed cone and 4 targets.
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of target is independent of gamma passing rate. It affirmed 
that PSQA using A16 microchamber and EBT3 film is suf-
ficient to verify the accuracy of the delivery.
Conclusion
We have demonstrated that SDVP including microcham-
ber and EBT3 film can be considered as PSQA to ensure the 
dosimetric and mechanical accuracy of small and multiple 
targets in CyberKnife with fixed collimators. In particular, 
the correction factors for A16 microchamber should be ap-
plied to the small fixed collimators less than 10 mm.
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